FCM
MACK

Farallon Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Farallon Capital Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-77,531
Closed -$4.45M – 105
2014
Q2 		$4.45M Buy
77,531
+37,200
+92% +$1.89M 0.06% 77
2014
Q1 		$1.6M Sell
40,331
-62,025
-61% -$2.65M 0.03% 79
2013
Q4 		$4.3M Hold
102,356
– – 0.09% 68
2013
Q3 		$3.06M Sell
102,356
-33,328
-25% -$1.17M 0.06% 72
2013
Q2 		$7.18M Buy
+135,684
New +$5.95M 0.14% 60

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Farallon Capital Management's MACK Position: Q3 2014 in Review

Farallon Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2014, closing a stake of 77,531 shares — an estimated $4.45M sold.

Farallon Capital Management first reported a position in MACK in Q2 2013 and held it in 5 quarters. The position peaked at $7.18M in Q2 2013. 132 funds tracked by Wall St. Rank hold MACK as of Q3 2014.

  • Farallon Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2014 after selling out during the quarter.
  • Farallon Capital Management sold 77,531 Merrimack Pharmaceuticals, Inc. shares in Q3 2014, an estimated $4.45M.
  • Farallon Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 5 quarters.
  • Farallon Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $7.18M in Q2 2013.
  • 132 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2014.

Based on Farallon Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.